Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...
Gilead is looking towards approval of lenacapavir as HIV PrEP after reporting near-perfect efficacy in the PURPOSE-1 and ...
Analyst Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report) and keeping the price target at ...
Discover why Gilead Sciences is a strong buy with potential blockbuster drugs in HIV and oncology, favorable valuation, and a ...
US pharmaceutical giant Gilead said Wednesday it had signed licensing deals with six generic drugmakers to produce and sell ...
GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...
Llenacapavir, a new HIV prevention injection, has been shown to have a 96% efficacy rate against the spread of the virus.
Gilead's partnership with generic manufacturers to lower the cost of its HIV drug lenacapavir is criticized for being too ...
Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...
The twice yearly lenacapavir injection will be available in 120 countries with a series of regulatory filings beginning by ...
United States pharmaceutical giant Gilead said on Wednesday it had signed licensing deals with six generic drugmakers to ...
A new, long-acting shot to prevent HIV could represent a turning point in efforts to reduce cases around the world — if ...